Disease Markers / 2024 / Article / Tab 2 / Review Article
Assessment of Antioxidant Enzyme Superoxide Dismutase (SOD) in Oral Cancer: Systematic Review and Meta-Analysis Table 2 The levels of antioxidant SOD activities or concentrations in various samples between the normal control group and patients with OSCC.
Author OSCC group Control group Measurement Method of assessment Stat sig Study Sample type Sample size Mean ± SD Sample size Mean ± SD Unit Study P -valueNagini et al. [16 ] Ti 24 13.18 ± 3.97 24 16.65 ± 3.36 Ua /mg pr Kakkar et al. [55 ] <0.001 Sabitha et al. [17 ] Er 12 4.8 12 6.3 — Misra and Fridovich (50% reduction at auto-oxidation) [56 ] <0.01 Subapriya et al. [18 ] Er 24 1.35 ± 0.13 24 2.49 ± 0.2 Ua /mg Hb Kakkar et al. [55 ] <0.05 Ti 24 14.55 ± 1.35 24 — Ua /mg pr — — Subapriya et al. [19 ] Er 6 1.53 ± 0.22 12 3.63 ± 0.35 Ua /mg Hb Kakkar et al. [55 ] <0.05 Beevi et al. [20 ] Er 15 10.07 ± 2.93 15 21.35 ± 2.80 Ub /100 mg pr Misra and Fridovich [56 ] <0.001 Manoharan et al. [21 ] Er 48 1.91 ± 0.1 16 2.29 ± 0.17 Ua /mg Hb Kakkar et al. [55 ] <0.01 Pl 48 3.27 ± 0.35 16 4.19 ± 0.31 Ua /ml Khanna et al. [22 ] Se 20 0.06 ± 0.12 20 0.43 ± 0.95 U/mg pr Marklund and Marklund [57 ] <0.001 Fiaschi et al. [23 ] Er 18 2.86 ± 0.928 20 3.55 ± 0.422 U/mg Hb Paoletti et al. [58 ] <0.05 Inhibition of superoxide-induced NADH oxidation Ti 18 8.55 ± 1.203 20 19.37 ± 3.092 U/mg pr <0.001 Elango et al. [24 ] Er 63 3.75 ± 0.41 45 5.94 ± 0.63 U/min/mg pr Marklund and Marklund [57 ] <0.001 Rasheed et al. [25 ] Er 24 7.25 ± 2.05 24 14.59 ± 1.43 Ua /100 mg pr Kakkar et al. [55 ] <0.001 Patel et al. [26 ] Er 126 2.023 ± 0.150 30 2.4709 ± 0.12 U/mg Hb Kakkar et al. [55 ] <0.05 Raghavendra et al. [27 ] Er 25 5.911 ± 1.419 25 8.145 ± 1.122 U/mg Hb Beauchamp and Fridovich [59 ] <0.001 Gokul et al. [28 ] Er 18 0.039 ± 0.010 25 0.0335 ± 0.01 Uc /mg Hb Marklund and Marklund [57 ] 0.053 Ti 18 2.45 ± 1.21 18 4.15 ± 2.31 Uc /mg pr <0.01 Giebułtowicz et al. [29 ] Sa 10 0.94 ± 0.99 30 0.6 ± 0.4 U/mg pr Beauchamp and Fridovich [59 ] Based on Formation of diformazan 0.0435 Sa 10 0.57 ± 0.07 30 0.53 ± 0.06 U/ml — — Srivastava et al. [30 ] Er 20 1.45 ± 0.112 20 2.280 ± 0.301 Ua /gHb Kakkar et al. [55 ] <0.001 Gurudath et al. [31 ] Cytosol &hemolysate 25 49.75 ± 7.88 25 178.4 ± 10.33 U/ml Ransel kit (Inhibition of superoxide-induced NADH oxidation) <0.001 Shilpasree et al. [32 ] Er 30 1.57 ± 0.14 30 2.91 ± 0.35 U/mn/mg pr Nandi et al. [60 ] (Inhibition of the auto-oxidation of pyrogallol) <0.0001 Shetty et al. [33 ] Sa 25 0.34 25 0.95 U/mg pr Beauchamp and Fridovich [59 ] <0.001 Bagul et al. [34 ] Se 25 3.92 ± 1.75 25 3.11 ± 1.95 Ud /ml Marklund and Marklund [57 ] 0.026 Rasool et al. [35 ] Er 30 0.15 ± 0.1 10 0.92 ± 1.79 ng/ml Spectrophotometry 0.21 Sa 30 0.61 ± 0.25 10 1.16 ± 0.1 ng/ml <0.001 Huo et al. [36 ] Er 25 0.035 25 0.028 U/mg Hb Marklund and Marklund [57 ] <0.05 Ti 15 2 15 5 U/mg pr <0.01 Shetty et al. [37 ] Se 50 2.09 ± 0.16 65 4.34 ± 0.06 U/mg of Hb NBT <0.001 Sa 50 0.07 ± 0.01 35 0.17 ± 0.03 U/mg pr Manasavena et al. [38 ] Pl 20 34.54 20 190.4 µ g/dlSun et al. [61 ] (Inhibition of a superoxide-induced NADH oxidation) — Singh et al. [39 ] Sa 50 0.027 ± 0.029 50 0.9911 ± 1.21 U/mg Beauchamp and Fridovich [59 ] & Almadori et al. [62 ] <0.01 Ganjre et al. [40 ] Se 30 2.3243 ± 0.99 30 4.252 ± 1.949 Ud /ml Marklund and Marklund [57 ] <0.05 Rai et al. [41 ] Pl 20 58.82 ± 3.135 20 189.45 ± 14.2 — Marklund and Marklund [57 ] <0.001 Thomas et al. [42 ] Pl 20 10.4 ± 2.4 20 18.28 ± 1.3 Ua /ml Kakkar et al. [55 ] <0.05 Shankarram et al. [43 ] Sa 25 4.17 ± 0.252 25 3.21 ± 0.2 U/ml ELISA kit (Cayman) — Misra et al. [44 ] Se 20 52.63 ± 4.02 20 189.45 ± 14.2 — Marklund and Marklund [57 ] <0.001 Nyamathi et al. [45 ] Plasma hemolyse 10 47.55 ± 10.32 10 194.35 ± 14.3 U/ml Suttle et al. [63 ] Ransel antioxidant enzyme kit <0.001 Srivastava et al. [46 ] Ti 20 14.28 ± 0.67 20 18.54 ± 0.54 Ua /g Hb Kakkar et al. [55 ] <0.001 Banerjee et al. [47 ] Mi 30 45.14 ± 0.88 20 98.5 ± 0.87 — Image J—Western blot films — Khan et al. [48 ] Se 50 0.13 ± 0.008 20 0.47 ± 0.001 ng/ml Kakkar et al. [55 ] <0.05 Sadaksharam [49 ] Se 29 196.9 ± 6.215 29 226.57 ± 6.74 U/ml Enzychrom™ assay kit <0.001 Subash et al. [50 ] Pl 35 710.2 ± 78.2 30 958.8 ± 159.9 U/g Hb Winterbourn et al. [64 ] <0.05 Basu et al. [51 ] Ly 30 29.27 ± 5.31 50 15.36 ± 2.43 U/mg of pr Misra and Fridovich [56 ] <0.001 Babiuch et al. [52 ] Sa 20 7.07 ± 5.3 20 2.36 ± 2.42 Ub /ml Misra and Fridovich [56 ] 0.002 Shahi et al. [53 ] Er 25 4.6 ± 2.2 45 10.8 ± 7.4 Ua /min/107 cells Choi et al. [65 ] <0.02 Sushma et al. [54 ] Se 100 1.49 ± 0.49 102 4.37 ± 1.43 Uc /100 mg pr Marklund and Marklund [57 ] <0.005
OSCC-oral squamous cell carcinoma, SD-standard deviation, Ti-tissue, Mi-mitochondria, Pl-plasma, Se-serum, Er-erythrocyte, Ly-lympholysate, Sa-saliva, Stat Sig-statistical significance, NBT-nitroblue tetrazolium, VDAC1 - voltage-dependent anion channel 1, and pr-protein. a The amount of enzyme required for 50% inhibition of the formation of NADH-phenazine methosulfate NBT formazan at 520 nm. b The amount of enzyme necessary to inhibit 50% epinephrine autoxidation. c The amount of enzyme necessary to cause 50% inhibition of pyrogallol autoxidation. d The amount of enzyme necessary to cause 50% inhibition of pyrogallol autoxidation per 30 ml of the assay mixture.